Click here for more articles by Kormedi.com. As constipation-related ads flood social media feeds with warnings of “bloated bellies full of toxins” and claims that “ignoring constipation will lead to ...

Benefits include reduced polyp size and severity of nasal symptoms at 24 weeks. HealthDay News — In adults with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal ...

Addition of the monoclonal antibody stapokibart significantly improved nasal polyps and nasal congestion in adults with uncontrolled chronic rhinosinusitis with nasal polyps, based on new data from ...

For severe chronic rhinosinusitis with nasal polyps, the novel monoclonal antibody stapokibart reduced symptoms and polyp size atop treatment with a daily intranasal corticosteroid. The polyp size ...

About The Study: Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart, a novel monoclonal antibody, reduced polyp size and ...

Thanks for your great work! I am recently been working on some research on polyp size measurement and find your dataset very valuable! I just want to ask where I can find the metadata, including the ...

CRSwNP often coexists with asthma, complicating treatment and reducing health-related quality of life. Standard therapies for CRSwNP, like nasal irrigation and corticosteroids, often inadequately ...

Viome Life Sciences, the leader in AI-powered, RNA-based diagnostics and precision nutrition and Scripps Research, the leader in accelerating the impact of fundamental research on human health, today ...

Please provide your email address to receive an email when new articles are posted on . EVEREST represents the first head-to-head study of these biologics for CRSwNP. Differences between the biologics ...

Lyra Therapeutics has lost >90% of its value since announcing the failed ENLIGHTEN-1 trial, despite the recent announcement of a clearly positive ENLIGHTEN-2. Considering a clearly positive phase 3, ...